1
|
Untch M, Aydeniz B, Franz H, Wolf F, Zoche H, Bartzke G. Die BLFG e. V. feiert 20-jähriges Bestehen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0042-116790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
2
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Loibl S, Mergler B, Eppel A, Solbach C, Lübbe KM, Eidtmann H, Rezai M, Hanusch C, Fehm T, Bartzke G, Burgmann DM, Krabisch P, Untch M, Nekljudova V, von Minckwitz G. Abstract P3-14-04: The choice of the indicator lesion impacts on the pCR rate – An analysis of 114 bilateral breast cancer patients treated within neoadjuvant trials. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with bilateral breast cancer are usually excluded from participating in clinical trials. The German Breast Group has traditionally included these patients into their neoadjuvant trials. However, little is known about the outcome of the non-indicator lesion.
Methods: We prospectively captured the information on bilateral breast cancer in our database and collected retrospectively the information from the original histological and surgical reports on tumor size, nodal status, histology, grading, hormone receptor and HER2 status as well as type of surgery and pathological complete response defined as ypT0 ypN0 and ypT0/is ypN0 because both definitions have been used in our clinical studies. The treating physician decided on clinical presentation, which side to be the indicator lesion on which response was assessed for the purpose of the study. The synchronous carcinoma in the contralateral breast is considered as the non-indicator lesion.
Results: From the 6727 patients treated within the Gepartrio, Geparquattro, Geparquinto, and Geparsixto study 157 (2.3%) patients have been identified with the diagnosis of bilateral carcinoma. From the 114 bilateral patients with any information on the non indicator lesion 104 with information on pCR on both sides were used for further analysis. The median age was 51 (range 29-74) years. There were more cT1 (48.5% vs 9.6%, p<0.001) and cN0 (60.0% vs 38.4%, p = 0.004) tumors in the group of the non-indicator lesion compared to the indicator lesion group. In 56% the molecular subtype was identical 86% had a luminal A like tumor of indicator as well as the non-indicator lesion, none of the luminal B-like indicator lesions were identical, 27% of the HER2+/ HR +, 58% in the HER2+/ HR- group and 66% of the triple negative indicator lesions had an identical non indicator lesion. In general the tumor tended to be of lower malignant potential in the non- indicator lesion. Lobular carcinomas (23.4% vs 16.7%, p = 0.205); grade 3 (26% vs 36.7%, p = 0.101), ER positive (72% vs 67%, p = 0.427), HER2-positive (23.9 vs. 35.7%, p = 0.068). Overall the pCR rate (ypT0 ypN) was 20.2% in the non-indicator lesion group vs 13.9% the indicator lesion group (p = 0.276) and ypT0/is ypN0 was 30.8% and 17.6%, respectively (p = 0.0388). 64.4% had no pCR in the indicator as well as the non-indicator lesion, 11.5% had a pCR in the indicator as well as the non-indicator lesion, 4.8% in the indicator alone and 19.2% in the non-indicator alone. Breast conserving surgery was performed more often for non-indicator lesions than for indicator lesions (59% vs 44.4%, p = 0.144).
Conclusion: In general the selection for the indicator lesion was based on tumor size, nodal status and inclusion criteria. Probably, some of the indicator lesions would not have qualified for trial participation. The pCR rate including non-invasive residuals was significantly higher for the non-indicator lesions probably due to smaller tumors and less nodal involvement at baseline. However, based on our data bilateral breast carcinomas should not be excluded from neoadjuvant clinical trials.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-04.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - B Mergler
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - A Eppel
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - C Solbach
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - KM Lübbe
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - H Eidtmann
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - M Rezai
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - C Hanusch
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - T Fehm
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - G Bartzke
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - D-M Burgmann
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - P Krabisch
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - M Untch
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - V Nekljudova
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| | - G von Minckwitz
- German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt
| |
Collapse
|
4
|
Untch M, Aydeniz B, Dimpfl T, Friedrich M, Wolff F, Zoche H, Bartzke G. München, 27.-29. Juli 2013. Bericht aus der Hauptsitzung der BLFG e.V. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1350990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
5
|
Riek S, Bachmann KH, Gaiselmann T, Fischer SC, Raestrup H, Buess GF, Bartzke G. Veress needle with optical protective shield and step system: A new safety concept in minimally invasive surgery. MINIM INVASIV THER 1999. [DOI: 10.3109/13645709909153169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
6
|
Abstract
129 patients with carcinoma of the vulva were treated at the Dept. of Obstetrics and Gynaecology from 1966-1985. FIGO stage I was observed in 21% of the cases, FIGO stage II in 50%, FIGO stage III in 10% and FIGO stage IV in 8% of the patients. In 10% of the patients, definite classification was not possible. Mean age at the onset of the disease was 66.2 years, the mean time of observation 63 months. Kraurosis of the vulva or leukoplakia were simultaneous phenomena recorded locally in 67% of the patients. Histological investigation showed squamous cell carcinoma in 93% of the cases. The tumours were most frequently observed on the labia and the clitoris. 98% of the patients underwent surgery, 64% radical vulvectomy with inguinal lymph node disection. 56% of the patients of this group had a 5-year survival rate, which was 47% for the entire group of patients. Wound healing disorders were the most frequently observed postoperative complications. Metastasis to the inguinal lymph nodes at the time of diagnosis is the critical point of the prognosis. In the absence of lymph node involvement, 68% of the patients achieved a 5-year survival, in the presence of lymph node involvement, the 5-year survival rate was only 13%. Results obtained by this study support the view, that radical surgery at the earliest possible time is the treatment of choice for carcinoma of the vulva.
Collapse
|
7
|
Bartzke G, Henne M, Beck T, Kreienberg R. Das Vulvakarzinom, operative Behandlung und klinische Ergebnisse. Arch Gynecol Obstet 1989. [DOI: 10.1007/bf02417403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Bartzke G, Rössler H, Seufert R, Möbus V, Kreienberg R. [Results of testing tumor resistance (in vitro--in vivo) in breast cancer]. Geburtshilfe Frauenheilkd 1987; 47:690-4. [PMID: 3678785 DOI: 10.1055/s-2008-1036025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
In-vitro sensitivity to cytostatics was tested in 281 carcinomas of the breast using the test method introduced by Volm. The Adriamycin 3H-uridine test system was chosen for the analysis. Altogether, 84.7% of the tumors were testable. A correlation with the subsequent in-vivo result was found in 219 of the breast cancer patients. Only 8% of the breast cancers were unequivocally sensitive to the test (uridine incorporation rate less than 55% for verification). The mean uridine incorporation rate was 577 CPM. Neither tumor size, lymph node status, nor the estrogen and progesterone receptor content of the tumor cells influenced the test result. With regard to the breast carcinoma, no relationship was found between the predictive information and the subsequent in-vivo response to chemotherapy. This applied to both short-term observation periods of three to six months as well as longer-term follow-ups. Furthermore, no connection was found between sensitivity in vitro and probability of recurrence (p = 0.69) under cytostasis. Probability of survival was higher among patients with tumors that were not sensitive to the test than among those with tumors which were (p less than or equal to 0.001). In the authors' experience the Volm chemosensitivity test only appears to furnish prognostic information about the breast carcinoma; in the light of their data the test appears rather unsuitable as an aid to deciding whether or not to institute cytostatic therapy.
Collapse
|
9
|
Bartzke G, Rössler H, Kreienberg R. Ergebnisse der Kurzzeit-Sensibilitätstestung maligner gynäkologischer und Mamma-Tumoren. Arch Gynecol Obstet 1987. [DOI: 10.1007/bf01783214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Abstract
Thrombocyte aggregation with normochromic anaemia occurred in a gravida III of 27 years of age with sonographically confirmed foetal hydrocephalus, after prostaglandin E2 cervical priming. The authors discuss the differential diagnostic possibilities, but the actual genesis of the changes remains unclear. Hence, it is recommended to check with particular care especially in induction of abortion, the coagulation system with the thrombocytes, over and above the well-known prostaglandin side effects. Special attention must be paid to the occurrence of allergic reactions, and it must always be borne in mind that induction of abortion after the 14th week of gestation is a risky matter (1).
Collapse
|
11
|
Burri C, Bartzke G, Coldewey J, Muggler E. Fractures of the tibial plateau. Clin Orthop Relat Res 1979:84-93. [PMID: 445922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
12
|
|